ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Betamethasone and gentamicin (United States: Not available): Drug information

Betamethasone and gentamicin (United States: Not available): Drug information
(For additional information see "Betamethasone and gentamicin (United States: Not available): Patient drug information" and see "Betamethasone and gentamicin (United States: Not available): Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: Canada
  • Valisone-G
Pharmacologic Category
  • Antibiotic, Topical;
  • Antibiotic/Corticosteroid, Topical;
  • Corticosteroid, Topical
Dosing: Adult
Corticosteroid-responsive dermatoses

Corticosteroid-responsive dermatoses: Apply to affected area 2 to 3 times daily.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Betamethasone and gentamicin (United States: Not available): Pediatric drug information")

Corticosteroid-responsive dermatoses, infected

Corticosteroid-responsive dermatoses, infected: Children and Adolescents: Topical: Apply to affected area 2 to 3 times daily.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in manufacturer's labeling.

Adverse Reactions

See individual agents.

Contraindications

Hypersensitivity to betamethasone, gentamicin, or any component of the formulation; viral diseases including chickenpox, herpes simplex, and vaccinia; tuberculosis of the skin; ophthalmic administration.

Warnings/Precautions

Concerns related to adverse effects:

• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.

• Contact dermatitis: Allergic contact dermatitis can occur and is usually diagnosed by failure to heal rather than clinical exacerbation; discontinue use if irritation occurs and treat appropriately.

• Hypersensitivity: Discontinue use for signs/symptoms of hypersensitivity (eg, irritation).

• Infection: Prolonged use may result in secondary bacterial or fungal superinfection due to immunosuppression. Lack of prompt clinical response may indicate resistance to therapy and warrant discontinuation of therapy and further evaluation.

• Ocular effects: Topical corticosteroids, including betamethasone, may increase the risk of posterior subcapsular cataracts and glaucoma. Monitor for ocular symptoms. Avoid contact with eyes.

• Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing syndrome (rare), hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, application to large surface areas, or prolonged use.

Other warnings/precautions:

• Appropriate use: For topical use only. Avoid use around eyes.

Warnings: Additional Pediatric Considerations

The extent of percutaneous absorption is dependent on several factors, including epidermal integrity (intact versus abraded skin), formulation, age of the patient, prolonged duration of use, and the use of occlusive dressings. Percutaneous absorption of topical steroids is increased in neonates (especially preterm neonates), infants, and young children. Infants and small children may be more susceptible to hypothalamic pituitary adrenal (HPA) axis suppression, intracranial hypertension, Cushing syndrome, or other systemic toxicities due to larger skin surface area to body mass ratio.

Product Availability

Not available in the US

Generic Equivalent Available: US

No

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Cream, External:

Valisone-G: Betamethasone 0.1% and gentamicin 0.1% (30 g) [contains cetostearyl alcohol, chlorocresol (chloro-m-cresol)]

Administration: Adult

Topical: For topical use only. Occlusive dressing may be used for refractory lesions or deep-seated dermatoses.

Administration: Pediatric

Topical: For topical use only. Avoid application in or around eyes. Occlusive dressing may be used for refractory lesions or deep-seated dermatoses.

Use: Labeled Indications

Note: Not approved in the United States.

Dermatoses: Topical management of secondarily infected allergic or inflammatory dermatoses responsive to corticosteroid therapy.

Metabolism/Transport Effects

Refer to individual components.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Betamethasone (Ophthalmic). Risk C: Monitor therapy

Nirmatrelvir and Ritonavir: May increase the serum concentration of Corticosteroids (Ophthalmic). Risk C: Monitor therapy

Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed. Risk C: Monitor therapy

Pregnancy Considerations

Refer to individual agents.

Breastfeeding Considerations

It is not known if betamethasone/gentamicin is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.

Monitoring Parameters

HPA axis suppression and adrenal insufficiency, especially in children; ocular symptoms.

Mechanism of Action

Refer to individual agents.

Pharmacokinetics (Adult Data Unless Noted)

Refer to individual agents.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Diprogenta;
  • (AR) Argentina: Bacticort | Diprogenta | Quiacort g | Sirotamicin bg;
  • (AT) Austria: Diprogenta;
  • (AU) Australia: Celestone vg;
  • (BG) Bulgaria: Betaderm | Betazongent | Diprogenta;
  • (BR) Brazil: Betogenta | Dibederm | Diprogenta | Dipropionato Betametasona+Sulfato Gentamicina | Dipropionato de betametasona + sulfato de gen | Dipropionato de betametasona + sulfato de gentamicina | Dipropionato de Betametasona+Sulfato de Gent. | Diprozil | Duotrat | Trok g;
  • (CH) Switzerland: Diprogenta;
  • (CL) Chile: Diprospan G | Labosona G | Mixgen;
  • (CO) Colombia: Besogen | Diprogenta | Trok g;
  • (CZ) Czech Republic: Belogent;
  • (DE) Germany: Diprogenta | Sulmycin mit celestan-v;
  • (DO) Dominican Republic: Beta biotic | Diprogenta | Gentacort;
  • (EC) Ecuador: Diprogenta | Mixgen;
  • (EE) Estonia: Diprogenta;
  • (EG) Egypt: Genmycin plus | Gentacure | Gentazone;
  • (ES) Spain: Celestoderm gentamicina | Diprogenta | Mibetin;
  • (ET) Ethiopia: B Mycin;
  • (FI) Finland: Celestoderm garamycin;
  • (GR) Greece: Celestoderm v with garamycin | Propiogenta;
  • (HK) Hong Kong: B+G | Beprogent | Beta-genta | Betacorten G | Betagent | Dermal G | Diprogenta | Progensone;
  • (HR) Croatia: Belogent | Diprogenta;
  • (HU) Hungary: Bedicortal;
  • (ID) Indonesia: Benoson g | Betasin | Biocort | Celestoderm v with garamycin | Derticort | Digenta | Diprogenta | Diprosta | Mastroson | Salgen Plus | Skilone | Skinal | Sonigen | Zensoderm;
  • (IL) Israel: Betacorten G | Diprogenta;
  • (IN) India: Betaderm-g | Betagel-g | Cortiderm-g | Dipgenta | Diprovate g | Exevate-g | Gentalene | Gentopic | Lupiderm-g | Propygenta | Sternon-g | Ultravate-g;
  • (IQ) Iraq: Betnosam g;
  • (IT) Italy: Brexagenbeta | Dermabiolene | Egerian | Fidagenbeta | Gentalyn beta | Gentam/betam Alm | Gentamicina e betametasone hexal | Gentamicina e betametasone pensa | Gentamicina e betametasone ratiopharm italia | Gentamicina/betametasone mylan generics | Kamelyn | Sterozinil | Tevabeta;
  • (JP) Japan: Betnoval g glaxosmithkline | Betnoval g sato | Cordel g | Dermosol g | Dexan | Dexan vg | Rinderon vg;
  • (KE) Kenya: Diprogenta;
  • (KR) Korea, Republic of: Acylo | Amol g a | Antasone | Aricort s | Asem-g | Ballenat | Baroma-g | Bedesta-g | Bencort | Bergen-g | Berocort-g | Beta | Betaderm-g | Betagen | Betagen-g | Betason-g | Better m | Betterderm g | Bistone-G | Br betacin | Broderm | Cabaclean | Caraben | Caravan | Cecolon-g | Cecoron G | Cecrason | Celasone | Celastone | Celecort | Celederm g | Celeron g | Celestone g | Celetone | Cellason | Celogen | Celton | Cerestin | Cestin | Ceston g | Cetasone | Chmaron-g | Clean g | Cleastone g | Clin-G | Clobegen-a | Combiderm G | Danagenta | Danason | Demacot-s | Derma g | Dermabetacin | Dermace g | Dermagood | Dermastop | Dermo beta | Dermonia | Diprogenta | Elskin | G ston | Genjistone | Genmason-g | Gentaderm | Gentrisone-g | Genzistone | I gee | Lavenderm | Lestone | Methagen | Modaderm-s | Myderm-g | Nivera | Novason | Perican-g | Restone | Saecrason | Saerogenta | Selecsking | Selston | Sensta-g | Sepiderm-gn | Seron | Setajina | Silcron g | Silcron-s | Silkron g | Stason-g | Sterocin g | Sterocin-g | Tragel g | Trifulg | Trigenta-g | Vameson-G | Verosin-g;
  • (KW) Kuwait: Diprogenta;
  • (LB) Lebanon: Diprogenta;
  • (LV) Latvia: Bedicort g | Betacorten G | Celestoderm v gara | Diprogenta;
  • (MX) Mexico: Diprosone g | Garamicina v | Valgeben;
  • (MY) Malaysia: Antasone | B Mycin | Beprogent | Betamethasone G | Betnesone g | Celestoderm v with garamycin | Dermal G | Diprogenta | Gentasone;
  • (NG) Nigeria: Becloderm g;
  • (PE) Peru: Diprogenta;
  • (PH) Philippines: Bactrigen | Diprogenta;
  • (PK) Pakistan: Austagent | Bactroid g | Beprogent | Bepronate | Betacline g | Betagenic | Betagent | Betamycin | Betasol g | Bg cure | Cutibet g | Digent | Digrit | Dipgen | Diprogenta | Effigenta | Encore G | Eponix G | Genivate | Genticyn b | Glovat g | Mysoderm | Proderm g | Provate-g | Vimrazin;
  • (PL) Poland: Bedicort g | Belogent | Diprogenta | Gebetil;
  • (PT) Portugal: Dibetop g | Diprogenta | Epione;
  • (PY) Paraguay: Crinex gen | Diprogenta | Gental beta;
  • (RO) Romania: Belogent | Diprogenta;
  • (RU) Russian Federation: Akriderm genta | Belogent | Betaderm | Celederm with gentamicin | Celestoderm v with garamycin | Diprogent;
  • (SA) Saudi Arabia: Celestoderm v gara | Diprogenta;
  • (SE) Sweden: Celeston valerat med gentamycin;
  • (SG) Singapore: Antasone | B Mycin | B-Tasone-G | Beprogent | Celestoderm v with garamycin | Diprogenta;
  • (SI) Slovenia: Belogent | Diprogenta | Kuterid G;
  • (SK) Slovakia: Belogent;
  • (TH) Thailand: Beprogenta | Betaderm-g | Betagen | Betagram | Betrocot | Diprogenta | Genta-betasone | Skinfect B;
  • (TR) Turkey: Belogent;
  • (TW) Taiwan: Anta | B Gencin | Bencogen | Bencort | Betaderm | Betagen | Betason-G | Biderlon | Dermaca | Diproderm | Diprogenta | Futusoa | Genderon | Gentacon | Gentaderm | Gentason | Gentasone | Gentesone | Menlin | Metagin | Sinbeta derm | Soft;
  • (UA) Ukraine: Belogent | Betason plus | Betazone plus | Celederm | Celektoderm vg with gentamicine | Celestoderm v with garamycin | Diprogent | Kuterid G;
  • (UY) Uruguay: Diprogenta | Mixgen;
  • (VE) Venezuela, Bolivarian Republic of: Beproderm | Betaderm con gentamicina | Betagemer | Celestoderm con gentalyn | Diprogenta;
  • (ZA) South Africa: Diprogenta;
  • (ZM) Zambia: Beprogent
  1. Valisone-G (betamethasone/gentamicin) [product monograph]. Laval, Quebec, Canada; August 2018.
Topic 89335 Version 108.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟